XVIVO has deepened the partnership with Professor Robert Porte´s liver transplant group at UMC Groningen. Their valuable perfusion data will be used to start an advanced analysis with the aim to construct a prescriptive model helping the surgeon making real-time decisions.
Professor Porte’s group developed the dHOPE-protocol for cold oxygenated liver perfusion, and recently published the excellent results of their randomised controlled clinical study in the New England Journal of Medicine. An extension of this protocol with controlled oxygenated rewarming and subsequent viability assessment of high-risk livers at body temperature (normothermia) requires advanced data-driven decision support. The self-learning analytical model will assist in the interpretation of the data generated in respect to previous perfusion outcomes.
The long-term goal of the XCEPT project is to establish a common database for perfusion data from all Liver Assist-machines. Connected clinics should be able to share their own data, as well as access all the data in the database, to use knowledge that is currently only locally available at each clinic.
“This is an important step forward in taking liver machine perfusion to the next level. It will facilitate the adoption of this technology by other centers and make clinical decisions more evidence-based and data driven, says Professor Robert Porte, UMC Groningen.
The model will serve as an additional tool for perfusionists and surgeons globally, by leverageing knowledge from multiple clinics around the world, in order to generate valuable insights. The insights can both facilitate a faster development of liver protocols and help the surgeon team make a better decision prior to transplantation. Additionally, the aim of the model will increase the use of high-risk organs that would otherwise be discarded.
“I am convinced that deeper analysis of perfusion data from XVIVO’s perfusion machines will provide valuable insights to the transplant teams which will enable more organs to be transplanted. The company is proud to have UMC Groningen as a partner in the project as Professor Porte and his team are at the forefront of liver perfusion ", says Dag Andersson, CEO of XVIVO.
Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.
